Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 3/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 4/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8221031 | 0.87 | GPR119 (0.56) | HDAC4GPR119MAPTPOLBHDAC6 | |
| SCHEMBL354648 | 0.85 | NPY2R (0.58) | HDAC4GPR119MAPTHDAC6HDAC1 | |
| SCHEMBL355575 | 0.83 | GPR119 (0.56) | HDAC4GPR119MAPTTP53POLB | |
| SCHEMBL355493 | 0.81 | HTT (0.52) | HDAC4GPR119MAPTHDAC6HDAC1 | |
| SCHEMBL17115033 | 0.80 | HDAC4 (0.54) | HDAC4GPR119MAPTTP53HDAC6 | |
| SCHEMBL354865 | 0.79 | GPR119 (0.55) | HDAC4GPR119MAPTTP53NPY2R | |
| SCHEMBL356303 | 0.77 | RBP4 (0.52) | HDAC4GPR119MAPTTP53HDAC6 | |
| SCHEMBL356667 | 0.77 | L3MBTL1 (0.43) | HDAC4GPR119MAPTTP53HDAC6 | |
| SCHEMBL355649 | 0.76 | TBK1 (0.43) | HDAC4GPR119MAPTTP53POLB | |
| SCHEMBL8226671 | 0.76 | GPR119 (0.52) | HDAC4GPR119MAPTTP53HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-19 | — | — | US | disclosed |
| WO-2009079593-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY1R, NPY5R | HDAC4 2569/4885GPR119 58/4885MAPT 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.